reports
Amphastar Pharmaceuticals Inc: 1 director
A director at Amphastar Pharmaceuticals Inc sold 12,500 shares at 47.178USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PPG PPG INDUSTRIES INC.
LITE LUMENTUM HOLDINGS INC.
UFPT UFP TECHNOLOGIES
PAA PLAINS ALL AMERICAN PIPELINE L.P.
GRC GORMAN-RUPP CO.
CPRT COPART INC.
BWA BORGWARNER INC.
BLL BALL CORPORATION
AMPH AMPHASTAR PHARMACEUTICALS INC
ACD ADECOAGRO S.A.
WTS WATTS WATER TECHNOLOGIES INC. CLASS A
XYL XYLEM INC.
ITT ITT INC.
ODC OIL-DRI CORP. OF AMERICA
PAY PAYMENTUS HLDGS INC
HRT HIRERIGHT HLDGS CORP
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
PX Forming Coiled Spring Between 4200 and 4050 We continue believe that upside is limited with the S&P 500 testing the top-end of our anticipated 2023 trading range (4165-4200). Our gameplan remains unchanged; reduce risk near resistance (where we are now) and add risk near support (the December 2022 lows at 3765 and/or the 2022 lows at 3490). Therefore, we continue to recommend a tactical overweight to defensives (Consumer Staples, Utilities, Health Care, and gold miners). A break above 4200 o...
LII LENNOX INTERNATIONAL INC.
SUM SUMMIT MATERIALS INC. CLASS A
AAON AAON INC.
XENE XENON PHARMACEUTICALS INC
VMC VULCAN MATERIALS COMPANY
VKTX VIKING THERAPEUTICS
VCEL VERICEL
FIX COMFORT SYSTEMS USA INC.
AMPH AMPHASTAR PHARMACEUTICALS INC
ADMA ADMA BIOLOGICS INC
XCRA CRH PLC ADS
MLM MARTIN MARIETTA MATERIALS INC.
BLD TOPBUILD CORP.
GMS GMS INC.
IBP INSTALLED BUILDING PRODUCTS INC.
SSD SIMPSON MANUFACTURING CO. INC.
TREX TREX COMPANY INC.
WSO WATSCO INC.
USLM U.S. LIME & MINERALS
MORF MORPHIC HOLDINGS
IDYA IDEAYA BIOSCIENCES
KDNY CHINOOK THERAPEUTICS INC
- Dave Nicoski
- Ross LaDuke
C CITIGROUP INC.
ZTS ZOETIS INC. CLASS A
VCEL VERICEL
TRIP TRIPADVISOR INC.
TGI TRIUMPH GROUP INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
PZZA PAPA JOHN'S INTERNATIONAL INC.
PLCE CHILDREN'S PLACE INC.
PACW PACWEST BANCORP
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MNRO MONRO INC
JWN NORDSTROM INC.
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
FTNT
DIS FORTINET INC.
CRM WALT DISNEY COMPANY
AMPH SALESFORCE.COM INC.
AAL AMPHASTAR PHARMACEUTICALS INC
WD AMERICAN AIRLINES GROUP INC.
MAS WALKER & DUNLOP INC.
MLM MASCO CORPORATION
LZB MARTIN MARIETTA MATERIALS INC.
AMWD LAZBOY INCORPORATED
CCL AMERICAN WOODMARK CORPORATION
COF CARNIVAL CORPORATION
BOOM CAPITAL ONE FINANCIAL CORPORATION
GM DMC GLOBAL INC
FTDR GENERAL MOTORS COMPANY
CRSR FRONTDOOR INC.
AAN CORSAIR GAMING
PRG THE AARONS COMPANY
ZIMVV PROG HOLDINGS INC
ENOV ZIMVIE INC
ENOVIS CORPORATION
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SM SM ENERGY COMPANY
RRC RANGE RESOURCES CORPORATION
HIBB HIBBETT SPORTS INC.
CRMT AMERICA'S CAR-MART INC.
CRK COMSTOCK RESOURCES INC.
AVD AMERICAN VANGUARD
AMPH AMPHASTAR PHARMACEUTICALS INC
FRO FRONTLINE LTD.
PLAB PHOTRONICS INC.
VVV VALVOLINE INC.
SD SANDRIDGE ENERGY INC.
PPIH PERMA PIPE INTERNATIONAL HOLDINGS
RCMT RCM TECHNOLOGIES
AMPY AMPLIFY ENERGY
TNK TEEKAY TANKERS
DZSI DZS INC
VHI VALHI INC.
NEXT NEXT CAPITAL
PRCT PROCEPT BIOROBOTICS CORP
AVDX AVIDXCHANGE HLDGS INC
RXST RXSIGHT INC
UDMY UDEMY INC
PL PLANET LABS PBC
LVLU LULUS FASHION LOUNGE HLDGS INC
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
WABC WESTAMERICA BANCORPORATION
VTNR VERTEX ENERGY INC.
SEAS SEAWORLD ENTERTAINMENT INC.
OFS OFS CAPITAL LLC
MANT MANTECH INTERNATIONAL CORPORATION CLASS A
LWAY LIFEWAY FOODS INC.
LNN LINDSAY CORPORATION
LAND GLADSTONE LAND CORP.
ITCI INTRA-CELLULAR THERAPIES INC.
DY DYCOM INDUSTRIES INC.
CVI CVR ENERGY INC.
CAR AVIS BUDGET GROUP INC.
AMPH AMPHASTAR PHARMACEUTICALS INC
AGM FEDERAL AGRICULTURAL MORTGAGE CORPORATION CLASS C
UFCS UNITED FIRE GROUP INC.
GOGLO GOLDEN OCEAN GROUP LTD
BSET BASSETT FURNITURE INDUSTRIES INC.
KBR KBR INC.
MRTN MARTEN TRANSPORT LTD.
UNVR UNIVAR SOLUTIONS INC.
VLO VALERO ENERGY CORPORATION
BKR BAKER HUGHES COMPANY CLASS A
LBRT LIBERTY OILFIELD SERVICE
TDW TIDEWATER INC
IEA INFRASTRUCTURE AND ENERGY ALTERNATIVES
LAZY LAZYDAYS HOLDINGS
NFE NEW FORTRESS ENERGY
TH TARGET HOSPITALITY CORP (A)
KLXE KLX ENERGY SERVICES
SHLS SHOALS TECHNOLOGIES GROUP
VAL VALARIS LTD
SRRA SIERRA ONCOLOGY INC
NE NOBLE CORP NEW
NCSM NCS MULTISTAGE HLDGS INC
SGLY SINGULARITY FUTURE TECHNOLOGY LTD
Amphastar Pharmaceuticals to Present at the Raymond James Human Health...
Amphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference RANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will be presenting at the Human Health Innovation Conference on Tuesday, June 22, 2021, at 2:00 pm Eastern time. This presentation w...
Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthca...
Amphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference RANCHO CUCAMONGA, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate Communications, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 2:30 pm East...
- Dave Nicoski
- Ross LaDuke
GILD GILEAD SCIENCES INC.
EXEL EXELIXIS INC.
ED CONSOLIDATED EDISON INC.
CNC CENTENE CORPORATION
CAG CONAGRA BRANDS INC.
AMPH AMPHASTAR PHARMACEUTICALS INC
ALKS ALKERMES PLC
THS TREEHOUSE FOODS INC.
USM UNITED STATES CELLULAR CORP
FCFS FIRSTCASH INC.
CUE CUE BIOPHARMA INC
REYN REYNOLDS CONSUMER PRODUCTS
Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary...
Amphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary RANCHO CUCAMONGA, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced the restructuring of its Chinese subsidiaries, primarily Amphastar Nanjing Pharmaceuticals Inc. (“ANP”). As part of the restructuring, Amphastar will buyback 26% of ANP’s equity currently held by third parties. In addition, ANP will spin-off its Chinese subsidiary, Nanjing Hanxin Pharmaceutical Technology Co., Ltd. and Hanxin’s subsidiaries (collectively, “Hanxin”). The ...
Amphastar Pharmaceuticals Reports Financial Results for the Three Mont...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021 Reports Net Revenues of $103.0 Million for the Three Months Ended March 31, 2021 RANCHO CUCAMONGA, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2021. First Quarter Highlights Net revenues of $103.0 million for the first quarterGAAP net income of $5.0 million, or $0.10 per share, for the first quarterAdjusted non-GAAP net income of $13.6 million, or $0.27 per sha...
Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate I...
Amphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection RANCHO CUCAMONGA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia (PCA), only for use with a compatible Alaris® infusion device, and for...
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold C...
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021 RANCHO CUCAMONGA, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2021 ended March 31, 2021, after the market closes on Thursday, May 6th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 876-9177, for international calls, dial (785) 424-1672, five minutes before the confer...
Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtua...
Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference RANCHO CUCAMONGA, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 pm Easte...
Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
Amphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection RANCHO CUCAMONGA, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Dextrose injection 50% in the 50 mL Luer-Jet® Prefilled Syringe System. For the past 40 years, the company has sold and marketed the product under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. Net revenues for the Company’s Dextrose injection for the yea...
Amphastar Pharmaceuticals Reports Financial Results for the Three Mont...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020 Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 RANCHO CUCAMONGA, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full-year ended December 31, 2020. Fourth Quarter Highlights Net revenues of $95.9 million for the fourth quarterGAAP net loss of $6.3 million, or $0.13 per share, for the fourth quarterAdjusted non-GAA...
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold ...
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021 RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. To access the conference call, dial toll free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the...
Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institu...
Amphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference RANCHO CUCAMONGA, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawatidewi, Executive V.P. Corporate Administration Center and Sales & Marketing, will participate in an Analyst-Moderated fireside chat at the Raymond James 2021 Institutional Healthcare Conference on Tuesday, March 2, 2...
Amphastar Announces Approval for Glucagon for Injection Kit, 1mg
Amphastar Announces Approval for Glucagon for Injection Kit, 1mg RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon...
Amphastar Pharmaceuticals Reports Financial Results for the Three Mont...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020 Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020 RANCHO CUCAMONGA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2020. Third Quarter Highlights Net revenues of $83.4 million for the third quarterGAAP net income of $3.9 million, or $0.08 per share, for the third quarterAdjusted non-GAAP net income of $7.6 million, or $0...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.